I sold for > 4.3 cents. And have subsequently been making money else where. Seriously no regrets.
I would like to see this company succeed, and I have kept it on the watch list. As I said to you before I would look to re enter post capital raise, and post confirmation Azercel trial data outcome.
The Azercel phase 1B trial to date is great. 4CR, 2SD, 1PD. They are awesome numbers and odds for patients having failed multiple lines of previous therapy. It also looks like they are set to get their 6 month durability tick as well.
If they had dosed 15 and were now saying they were submitting to FDA for registrational. I would consider buying back in.
All that aside.
At current cash burn. This company needs to raise $80M to get Azercel majority way through registrational trial and sell it to someone else or partner with BP. They raised $20M with a pseudo debt for shares deal. Cap and collar pricing. 4 cents to 2 cent range. (I don't have the exact numbers handy to quote). They are spending $17-$20 a quarter. So they've kicked the can down the road for 3 months.
I don't see this rally holding (much like all the others). As everyone can still see the moment the share price has strength. They'll seek to raise more capital.
Shortest path to a registrational trial is to recruit 3 more patients for the Phase 1B. To get to the 10 they need. It took them 5.5 months to do this. That's August 2025 best estimates we'll see the next Azercel update. And not so coincidence, that's approximately the time when their money runs out again.
As above, once the cash is sorted out (if it can be), and phase 1 Azercel data is sorted and confirmed (Seems likely). I'll reassess if I re entry. And I wont be crying over spilt milk if the share price is higher then 4.3 cents. (Re entering at a higher price but lower risk position, if this survives).
Where things are at now, this remains an exterme risk stock. All or nothing play. $330M market cap, looks expensive for what it is.
DYOR not advice.
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)